Lantern Pharma Inc. Form 8-K Summary
Business Context and Reporting Period
Lantern Pharma Inc. (LTRN), a Delaware corporation and emerging growth company, filed this Current Report on Form 8-K on July 3, 2025. The filing reports the entry into a material definitive agreement to establish an "at-the-market" (ATM) equity offering program.
Key Financial Metrics
This filing does not contain audited financial statements, revenue, profit, cash flow, or debt metrics. The primary financial data point disclosed is the authorization of a potential capital raise of up to $15,530,000 in aggregate gross proceeds from the sale of common stock.
Material Changes and Agreement Details
- Agreement Type: ATM Sales Agreement with ThinkEquity LLC acting as the sales agent.
- Offering Size: Up to $15,530,000 maximum aggregate offering price.
- Commission: The Company will pay the Agent a commission of 3.0% of the aggregate gross proceeds.
- Sale Method: Shares may be sold directly on or through The Nasdaq Capital Market or other existing trading markets at prevailing market prices.
- Termination: The agreement terminates upon the sale of all shares or by either party giving ten days' prior notice.
Guidance, Outlook, and Risks
The filing does not provide specific financial guidance or management commentary on future operating results. Key contingencies and risks include:
- The Company is not obligated to sell any shares under the agreement.
- Sales are subject to market conditions and the Company's discretion to set minimum sale prices.
- The Company has agreed to indemnify the Agent against certain liabilities under the Securities Act.
Investor Verification Checklist
- Verify the current market price of LTRN common stock to assess potential dilution impact.
- Review the Company's most recent 10-Q or 10-K to understand current cash runway and liquidity needs driving this offering.
- Confirm the status of the underlying Form S-3 registration statement (File No. 333-279718) declared effective on June 10, 2024.
- Monitor future filings for actual sales volumes and proceeds generated under the ATM program.